STK16 and cancer: Immunohistochemistry and western blot assays were performed to assess the expression levels of c-MYC and Ki-67 (representing the proliferation ability of cancer cells), showing that loss of STK16 significantly restrained the expression levels of c-MYC and Ki-67 in vivo (Fig. 7E-F).